ZP123 increases gap junctional conductance and prevents reentrant ventricular Tachycardia during myocardial ischemia in open chest dogs

Journal of Cardiovascular Electrophysiology

Volumn 14, Issue 5, 2003, Pages 510-520

  Xing, Dezhi ^a   Kjølbye, Anne Louise ^b   Nielsen, Morten S ^c   Petersen, Jørgen S ^b   Harlow, Kenneth W ^b   Holstein Rathlou, Niels Henrik ^c   Martins, James B ^a  

^a UNIVERSITY OF IOWA   (United States)

^b Zealand Pharma AS   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Gap junctions; Myocardial ischemia; Ventricular tachycardia

Indexed keywords

ANTIARRHYTHMIC PEPTIDE; CHLORALOSE; ROTIGAPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOG; DRUG INFUSION; DRUG MECHANISM; ELECTROCARDIOGRAM; FEMALE; GAP JUNCTION; GUINEA PIG; HEART CONDUCTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART VENTRICLE TACHYCARDIA; HEMODYNAMICS; MALE; MASS SPECTROMETRY; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; REENTRY ARRHYTHMIA; REPRODUCIBILITY; VOLTAGE CLAMP;

ANIMALS; BLOOD PRESSURE; CELL MEMBRANE; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; GAP JUNCTIONS; HEART BLOCK; HEART CONDUCTION SYSTEM; INCIDENCE; INFUSIONS, INTRAVENOUS; MALE; MODELS, CARDIOVASCULAR; MYOCARDIAL ISCHEMIA; MYOCYTES, CARDIAC; OLIGOPEPTIDES; REPRODUCIBILITY OF RESULTS; STATISTICS; TACHYCARDIA, VENTRICULAR;

EID: 0038662776     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1540-8167.2003.02329.x     Document Type: Article

References (30)

1. Bayes DL, Coumel P, Leclercq JF: Ambulatory sudden cardiac death: Mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 1989;117:151-159.
2. Cairns JA, Connolly SJ, Roberts R, Gent M: Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations: CAMIAT. Canadian Amiodarone Myocardial Infarction Trial Investigators. Lancet 1997;349:675-682.
3. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL: Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-788.
4. Beardslee MA, Lerner DL, Tadros PN, Laing JG, Beyer EC, Yamada KA, Kleber AG, Schuessler RB, Saffitz JE: Dephosphorylation and intracellular redistribution of ventricular connexin43 during electrical uncoupling induced by ischemia. Circ Res 2000;87:656-662.
5. Huang XD, Sandusky GE, Zipes DP: Heterogeneous loss of connexin43 protein in ischemic dog hearts. J Cardiovasc Electrophysiol 1999;10:79-91.
6. Kaprielian RR, Gunning M, Dupont E, Sheppard MN, Rothery SM, Underwood R, Pennell DJ, Fox K, Pepper J, Poole-Wilson PA, Severs NJ: Downregulation of immunodetectable connexin43 and decreased gap junction size in the pathogenesis of chronic hibernation in the human left ventricle. Circulation 1998;97:651-660.
7. Peters NS, Green CR, Poole-Wilson PA, Severs NJ: Reduced content of connexin43 gap junctions in ventricular myocardium from hypertrophied and ischemic human hearts. Circulation 1993;88:864-875.
8. Peters NS, Coromilas J, Severs NJ, Wit AL: Disturbed connexin43 gap junction distribution correlates with the location of reentrant circuits in the epicardial border zone of healing canine infarcts that cause ventricular tachycardia. Circulation 1997;95:988-996.
9. Guerrero PA, Schuessler RB, Davis LM, Beyer EC, Johnson CM, Yamada KA, Saffitz JE: Slow ventricular conduction in mice heterozygous for a connexin43 null mutation. J Clin Invest 1997;99:1991-1998.
10. Lerner DL, Yamada KA, Schuessler RB, Saffitz JE: Accelerated onset and increased incidence of ventricular arrhythmias induced by ischemia in Cx43-deficient mice. Circulation 2000;101:547-552.
11. Dhein S, Tudyka T: Therapeutic potential of antiarrhythmic peptides. Cellular coupling as a new antiarrhythmic target. Drugs 1995;49:851-855.
12. Aonuma S, Kohama Y, Makino T, Fujisawa Y: Studies of heart. XXI. Amino acid sequence of antiarrhythmic peptide (AAP) isolated from atria. J Pharmacobiodyn 1982;5:40-48.
13. Aonuma S, Kohama Y, Akai K, Komiyama Y, Nakajima S, Wakabayashi M, Makino T: Studies on heart. XIX. Isolation of an atrial peptide that improves the rhythmicity of cultured myocardial cell clusters. Chem Pharm Bull (Tokyo) 1980;28:3340-3346.
14. Muller A, Schaefer T, Linke W, Tudyka T, Gottwald M, Klaus W, Dhein S: Actions of the antiarrhythmic peptide AAP10 on intercellular coupling. Naunyn Schmiedebergs Arch Pharmacol 1997;356:76-82.
15. Muller A, Gottwald M, Tudyka T, Linke W, Klaus W, Dhein S: Increase in gap junction conductance by an antiarrhythmic peptide. Eur J Pharmacol 1997;327:65-72.
16. Dhein S, Manicone N, Muller A, Gerwin R, Ziskoven U, Irankhahi A, Minke C, Klaus W: A new synthetic antiarrhythmic peptide reduces dispersion of epicardial activation recovery interval and diminishes alterations of epicardial activation patterns induced by regional ischemia. A mapping study. Naunyn Schmiedebergs Arch Pharmacol 1994;350:174-184.
17. 90 during ischemia-reperfusion in rabbit hearts. J Cardiovasc Pharmacol 2002;40:770-779.
18. Dhein S, Manicone N, Muller A, Gerwin R, Ziskoven U, Irankhahi A, Minke C, Klaus W: A new synthetic antiarrhythmic peptide reduces dispersion of epicardial activation recovery interval and diminishes alterations of epicardial activation patterns induced by regional ischemia. A mapping study. Naunyn Schmiedebergs Arch Pharmacol 1994;350:174-184.
19. Dikshit M, Srivastava R, Kundu B, Mathur KB, Kar K: Antiarrhythmic and antithrombotic effect of antiarrhythmic peptide and its synthetic analogues. Indian J Exp Biol 1988;26:874-876.
20. Kohama Y, Okimoto N, Mimura T, Fukaya C, Watanabe M, Yokoyama K: A new antiarrhythmic peptide, N-3-(4-hydroxyphenyl)propionyl Pro-Hyp-Gly-Ala-Gly. Chem Pharm Bull (Tokyo) 1987;35:3928-3930.
21. Kohama Y, Kuwahara S, Yamamoto K, Okabe M, Mimura T, Fukaya C, Watanabe M, Yokoyama K: Effect of N-3-(4-hydroxyphenyl)propionyl Pro-Pro-Gly-Ala-Gly on calcium-induced arrhythmias. Chem Pharm Bull (Tokyo) 1988;36:4597-4599.
22. Ronsberg MA, Saunders TK, Chan PS, Cervoni P: The antiarrhythmic effect of antiarrhythmic peptide (Gly-Pro-4Hyp-Gly-Ala-Gly) and its analog on chemically-induced arrhythmias in mice. Med Sci 1986;14:350-351.
23. Cable DG, Rath TE, Dreyer ER, Martins JB: Refractory period response of cardiac Purkinje tissue to alpha 1- and alpha 2-adrenergic influences. Am J Physiol 1994;267:H376-H382.
24. Arnar DO, Bullinga JR, Martins JB: The role of the Purkinje system in spontaneous ventricular tachycardia during acute ischemia in a canine model. Circulation 1997:96:2421-2429.
25. Arnar DO, Xing D, Lee H, Martins JB: Prevention of ischemic ventricular tachycardia of Purkinje origin: Role for alpha-2 adrenoceptors in Purkinje. Am J Physiol 2001;280:H1182-H1190.
26. Argentieri T, Cantor E, Wiggins JR: Antiarrhythmic peptide has no direct cardiac actions. Experientia 1989;45:737-738.
27. Weng S, Lauven M, Schafer T, Polontchouk L, Grover R, Dhein S: Pharmacological modification of gap junction coupling by an antiarrhythmic peptide via protein kinase C activation. FASEB J 2002;16:1114-6.
28. Saffitz JE: Electrophysiologic remodeling: What happens to gap junctions? J Cardiovasc Electrophysiol 1999;10:1684-1687.
29. Kleber AG, Riegger CB, Janse MJ: Electrical uncoupling and increase of extracellular resistance after induction of ischemia in isolated, arterially perfused rabbit papillary muscle. Circ Res 1987;61:271-279.
30. Wilders R, Wagner MB, Golod DA, Kumar R, Wang YG, Goolsby WN, Joyner RW, Jongsma HJ: Effects of anisotropy on the development of cardiac arrhythmias associated with focal activity. Pflugers Arch 2000;441:301-312.